- Pembrolizumab, sold
under the
brand name
Keytruda, is a
humanized antibody, more
specifically a PD-1 inhibitor, used in
cancer immunotherapy that treats...
- 6
blockbuster drugs or products, each with over $1
billion in revenue:
Keytruda (pembrolizumab), a
humanized antibody used in
cancer immunotherapy that...
- Steenhuysen,
Julie (16
April 2023). "Moderna/Merck
cancer vaccine plus
Keytruda delays skin
cancer return". Reuters.
Retrieved 6 July 2023. "Moderna and...
-
sebaceous carcinomas. In May 2017 the FDA
approved an
immunotherapeutic called Keytruda (pembrolizumab) (PD-1 inhibitor) for
patients with
unresectable or metastatic...
- head and neck cancer, and Hodgkin's lymphoma.
Pembrolizumab (brand name
Keytruda) is
another PD-1
inhibitor that was
approved by the FDA in 2014 and was...
- 2024.
Retrieved March 30, 2025. "PADCEV® (Enfortumab Vedotin-ejfv) with
KEYTRUDA® (Pembrolizumab)
Approved by FDA as the
First and Only ADC Plus PD-1 to...
-
Actemra (Hoffmann-La Roche/Chugai),
Entyvio (Millenium Pharma/Takeda) and
Keytruda (Merck/MSD), are
licensed drugs.[failed verification] In 2010, LifeArc...
-
allowing BMS to
better compete against Merck & Co's
cancer rival treatment,
Keytruda. In
early January 2019, the
company announced it
would acquire Celgene...
-
Angelica (2
February 2018). "Merck
posts mixed fourth-quarter
results as
Keytruda sales skyrocket". CNBC.
Merck & Co., Inc US
Securities and
Exchange Office...
- Commission.
Examples of
licensed monoclonal antibodies include:
Pembrolizumab (
Keytruda)
binds to PD-1
proteins found on T cells.
Pembrolizumab blocks PD-1 and...
